Historical Review of Research and Treatment of Gastric Cancer in Japan: Clinical Aspect

  • Toshifusa Nakajima
Chapter

Summary

The history of basic and clinical research in gastric cancer originated from the 19th century in Europe, but surprisingly rapid response to this flow abroad occurred in Japan in every aspect of research and treatment of this disease. Researchers in early days devoted their best efforts to conquer the most frequent cancer in Japan. Diagnosis of gastric cancer has been highly elaborated with the aid of the double-contrast method of X-ray fluoroscopy and meticulous endoscopic apparatus, which facilitated both minimum and extended surgery according to the extent of disease. Effective anticancer drugs are available now, some of which were developed originally in our country. Daily use of gene diagnosis and treatment could be expected in the near future. Now we can enjoy a high level of treatment results in the fields of surgery and chemotherapy and should try to establish a global standard of diagnosis and treatment of gastric cancer. International corroboration is mandatory to achieve these goals, and we could expect the International and Japanese Gastric Cancer Associations and the WHO Collaborating Center for Primary Prevention, Diagnosis and Treatment of Gastric Cancer (chaired by Suemasu, Maruyama, Sasako) will take a leading role in this field. Gastric cancer still remains one of the prevailing cancers in our country, and our next goal should be based in prophylaxis to reduce the incidence of gastric cancer.

Keywords

Gastric Cancer Clin Oncol Gastric Cancer Patient Early Gastric Cancer Advanced Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ishikawa K, Sakai S (1996) Historical review. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 1–19Google Scholar
  2. 2.
    Shirakabe H, Nishizawa M (1996) X-ray and nuclear diagnosis. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 191–217Google Scholar
  3. 3.
    Shirakabe H, Nishizawa N (1996) Mass-screening system. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 349–360Google Scholar
  4. 4.
    Ariga K, Takahashi A (1965) Mass screening of gastric cancer (in Japanese). Nanzando, Tokyo, pp 4–5Google Scholar
  5. 5.
    Shirakabe H (1963) Merit and demerit of double contrast method in upper gastrointestinal tract series (in Japanese). Rinshou Kenkyu 40:768–770Google Scholar
  6. 6.
    Sakita T, Takasu Y (1996) Endoscopy, cytology and biopsy diagnosis of gastric cancer. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 241–305Google Scholar
  7. 7.
    Uji T (1953) Study on the photography of gastric mucosa and its clinical application (in Japanese). Tokyo Igaku Zasshi 61:135–142Google Scholar
  8. 8.
    Hirschowitz B, Curtiss LE, Peters CW, Pollard HM (1958) Demonstration of new gastroscope, the “fiberscope.” Gastroenterology 35:50–53PubMedGoogle Scholar
  9. 9.
    Tasaka S (1962) Nation-wide registry of early gastric cancer (in Japanese). Gastroenterol Endosc 4:4–14Google Scholar
  10. 10.
    Borrmann R (1926) Geschwulste des Magens und Duodenums. In: Handbuch der speziellen pathologischen Anatomie und Histologie, vol 4. Springer, Berlin, pp 812–1054Google Scholar
  11. 11.
    Murakami T, Nagayo T, Kanai S, et al (1963) Macroscopic classification of early gastric cancer and histopathological examination (in Japanese). Shoukakibyou no Rinshou 5:703–711Google Scholar
  12. 12.
    Inoue Y (1936) Lymphatic system of gastroduodenum, pancreas and diaphragma (in Japanese). Kaibougakuzasshi 9:35–123Google Scholar
  13. 13.
    Ayabe M (1949) So-called early gastric cancer (in Japanese). Rinshou to Kenkyu 26:514–525Google Scholar
  14. 14.
    Schlemper R, Itabashi M, Kato Y, et al (1997) Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 349:1725–1729CrossRefPubMedGoogle Scholar
  15. 15.
    Kato Y (1999) International concern to early gastric cancer-attempt to standardization of histological diagnosis (in Japanese). Dig Endosc 11:295–299Google Scholar
  16. 16.
    Sugano H, Kato Y (1996) Historical aspect of pathology. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 625–641Google Scholar
  17. 17.
    Kuipers E (1999) Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 13:3–11PubMedGoogle Scholar
  18. 18.
    Kawamata K (1871) History of gastric cancer (in Japanese). Igakutosho Shuppan, TokyoGoogle Scholar
  19. 19.
    Takahama T, Wada T (1996) Surgical treatment. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 371–395Google Scholar
  20. 20.
    Kondo T (1899) An experiment in gastric cancer surgery (in Japanese). Nihon Gekagakkai Zasshi 1:234–252Google Scholar
  21. 21.
    Miyake H (1914) Treatment result of gastric cancer with surgery (in Japanese). Chugai Igakushinpo 823:901–902Google Scholar
  22. 22.
    Mutou M (1965) Surgical aspect of gastric cancer (in Japanese). Kanehara Shuppan, TokyoGoogle Scholar
  23. 23.
    Tomoda M (1953) Surgery of gastric cancer (in Japanese). Rinshou to Kenkyu 30:300–308Google Scholar
  24. 24.
    Pichlmayr R, van Alste E (1976) Die totale Gastrektomie als Regeloperation beim operablen Magencarcinom. Langenbecks Arch Klin Chir 342:227–231Google Scholar
  25. 25.
    Kuru M (1935) Statistical consideration of radical surgery for gastric cancer (in Japanese). Rinshou IIgaku 23:390–390Google Scholar
  26. 26.
    Kajitani T (1944) Lymph node metastasis of gastric cancer (in Japanese). Nihon Gekagakkai Zassi 45:15–16Google Scholar
  27. 27.
    Jinnai D (1961) Extended radical operation of gastric cancer, with special emphasis on the lymph node dissection (in Japanese). Gekashinryou 3:556–556Google Scholar
  28. 28.
    Nakayama K (1949) Gastrectomy with fixation of posterior gastric wall to the pancreas (in Japanese). Shujutu 3:51–56Google Scholar
  29. 29.
    Miyagi J (1928) A variation of gastrectomy. Nihon Gekagakkai Zasshi 29:786–786Google Scholar
  30. 30.
    Gouzi J, Huguier M, Fagniez P, et al (1989) Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 209:162–166PubMedGoogle Scholar
  31. 31.
    Bozzetti F, Marubini E, Bonfanti G, et al (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 230:170–178CrossRefPubMedGoogle Scholar
  32. 32.
    Miwa K (1996) Nationwide registry of gastric cancer and statistics. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 465–506Google Scholar
  33. 33.
    Weinberg J, Greaney E (1950) Identification of regional lymph nodes by means of a vital dye during surgery of gastric cancer. Surg Gynecol Obstet 90:561–567PubMedGoogle Scholar
  34. 34.
    Kajitani T, Yamada S (1955) Clinical application of vital lymph node staining with sky blue to radical surgery for gastric cancer (in Japanese). Gan no Rinsho 1:513–516Google Scholar
  35. 35.
    Uchida H (1971) A study on lymphography regional to the stomach and adjacent organs (in Japanese). Nihon Igakuhoushasen Gakkaishi 31:259–277Google Scholar
  36. 36.
    Hauser W, Atkins H, Richards P (1969) Lymph node scanning with 99mTc-sulfur colloid. Radiology 92:1369–1371PubMedGoogle Scholar
  37. 37.
    Aikou T, Saihara T, Nishi M (1983) Lymph flow at the cardia and lymphatic metastasis of cardiac cancer with special reference to the use of radio-isotope lymphography (in Japanese). Rinpagaku 6:248–252Google Scholar
  38. 38.
    Takahashi S, Takahashi T, Hagiwara A, et al (1987) Lymph node dissection according to the location of gastric cancer with staining of lymph nodes with micro-active carbon particles (in Japanese). Shoukakigeka Gakkai Zasshi 20:720–725Google Scholar
  39. 39.
    Siewert J, Bottcher K, Roder J, et al (1993) Prognostic relevance of systemic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 80:1015–1018PubMedGoogle Scholar
  40. 40.
    Pacelli F, Doglietto G, Bellantone R, Alfieri S, Sgadari A, Crucitti F (1993) Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br J Surg 80:1153–1156PubMedGoogle Scholar
  41. 41.
    Roukos D (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6:46–56CrossRefPubMedGoogle Scholar
  42. 42.
    Sierra A, Regueira F, Hernandez-Lizoain J, et al (2003) Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. Ann Surg Oncol 10:219–226CrossRefPubMedGoogle Scholar
  43. 43.
    Bunt A, Hermans J, Boon M, et al (1994) Evaluation of the extent of lymphadenectomy in a randomized trial of Western-versus Japanese-type surgery in gastric cancer. J Clin Oncol 12:417–422PubMedGoogle Scholar
  44. 44.
    Cuschieri A, Weeden S, Fielding J, et al (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79:1522–1530CrossRefPubMedGoogle Scholar
  45. 45.
    Bonenkamp J, Hermans J, Sasako M, et al (1999) Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 340:908–914CrossRefPubMedGoogle Scholar
  46. 46.
    Pacelli F, Sgadari A, Doglietto G (1999) Surgery for gastric cancer. N Engl J Med 341:538–538CrossRefPubMedGoogle Scholar
  47. 47.
    Brennan M (1999) Lymph-node dissection for gastric cancer. N Engl J Med 340:956–958CrossRefPubMedGoogle Scholar
  48. 48.
    Marubini E, Bozzetti F, Bonfanti G, et al Gastrointestinal Tumor Study Group (2002) Lymphadenectomy in gastric cancer: prognostic role and therapeutic implications. Eur J Surg Oncol 28:406–412CrossRefPubMedGoogle Scholar
  49. 49.
    Yoshioka H, Miyazaki S (1952) A case report of gastric cancer treated with pancreatoduodenectomy (in Japanese). Rinshou Geka 7:231–235Google Scholar
  50. 50.
    Kajitani T, Hoshino T, (1952) An experience of pancreatoduodenectomy (in Japanese). Rinshougeka 7:231–235Google Scholar
  51. 51.
    Appleby L (1953) The coeliac axis in the expansion of the operation for gastric carcinoma. Cancer (Phila) 6:704–707PubMedGoogle Scholar
  52. 52.
    Wada T, Katayama K, et al (1978) Extent of lymph node dissection in gastric cancer (in Japanese). Geka 40:154–159Google Scholar
  53. 53.
    Ohashi I, Takagi K, Konishi T, et al (1976) 5 year survivors of gastric cancer patients with para-aortic lymph node metastasis (in Japanese). Nihon Shoukakigeka Gakkaishi 9:507–512Google Scholar
  54. 54.
    Aikou T, Yoshinaka H, Shimazu H (1988) Significance and indication of para-aortic lymph node metastasis from esophago-gastric cancer (in Japanese). Gan no Rinshou 34:1677–1683Google Scholar
  55. 55.
    Yamada S, Okajima K, Isozaki H, et al (1989) Evaluation on the indication of para-aortic lymph node dissection in gastric cancer surgery (in Japanese). Nihon Gekagakkaishi 90:1314–1317Google Scholar
  56. 56.
    Takahashi S (1990) Study on the pattern of lymph node metastasis based on the analysis of gastric cancer patients treated with para-aortic dissection (in Japanese). Nihon Gekagakkaishi 91:29–35Google Scholar
  57. 57.
    Keighley M, Moore J, Roginski C, et al (1984) Incidence and prognosis of N4 node involvement in gastric cancer. Br J Surg 71:863–866PubMedGoogle Scholar
  58. 58.
    Ohashi I, Takagi K, Kajitani T (1984) Indication and method of left upper abdominal evisceration for advanced gastric cancer (in Japanese). Shoukakigeka 7:1535–1542Google Scholar
  59. 59.
    Ohyama S, Nakajima T, Ohta K, et al (1994) Left upper abdominal evisceration (in Japanese). Gan to Kagakuryouhou 21:1781–1786Google Scholar
  60. 60.
    Japanese Gastric Cancer Association (2001, 2004) Treatment guidelines of gastric cancer, 1st and 2nd edns (in Japanese). Kanehara Shuppan, TokyoGoogle Scholar
  61. 61.
    Takekoshi T, Tajiri H, Ohashi K, et al (1981) Comparative study of biopsy specimen and histological examination: usefulness of endoscopic double snare polypectomy (in Japanese). Nihon Ganchiryougakkaishi 16:395Google Scholar
  62. 62.
    Hirao M, Takakuwa R, Kawashima H, et al (1988) Endoscopic mucosal resection with local injection of hyper saline solution for early gastric cancer (in Japanese). I to Chou 23:399–409Google Scholar
  63. 63.
    Tada M, Murata M, Murakami F, et al (1984) Developing strip-off biopsy (in Japanese). Shoukaki Naishikyou 26:833–836Google Scholar
  64. 64.
    Takeshita K, Inoue H, Honda T, et al (1993) Endoscopic mucosal resection of gastric cancer (in Japanese). Shujutu 47:1537–1546Google Scholar
  65. 65.
    Goh P, Tekant Y, Kum C, et al (1992) Totally intra-abdominal laparoscopic Billroth II gastrectomy. Surg Endosc 6:160PubMedGoogle Scholar
  66. 66.
    Kitano S, Iso Y, Moriyama M, et al (1994) Laparpscopy-assisted Billroth I gastrectomy. Surg Laparoscop Endoscop 4:146–148Google Scholar
  67. 67.
    Uyama I, Ogiwara H, Takahara T, et al (1994) Laparoscopic and minilaparotomy Billroth I gastrectomy for gastric ulcer using an abdominal wall-lifting method. J Laparoscop Surg 4:441–445Google Scholar
  68. 68.
    Japanese Gastric Cancer Association (2001) Commentary of gastric cancer treatment guidelines (in Japanese). JGCA, TokyoGoogle Scholar
  69. 69.
    Japanese Gastric Cancer Association (1995) Japanese classification of gastric carcinoma. Kanehara, TokyoGoogle Scholar
  70. 70.
    Kurihara M, Nakajima T (1981) Chemotherapy for gastric cancer (in Japanese). Shinkouigaku Shuppan, TokyoGoogle Scholar
  71. 71.
    Furue H (1996) Chemotherapy. In: Gastric cancer in Japan (in Japanese). Kanehara Shuppan, Tokyo, pp 423–457Google Scholar
  72. 72.
    Ishidate M, Sakurai Y, Yoshida T, et al (1952) Experimental study of chemotherapy using Yoshida Sarcoma(III); suppression effect of nitrogen-mustard N-oxide (in Japanese). Gann 43:171–174Google Scholar
  73. 73.
    Macdonald JS, Woolley PV, Smythe T, et al (1979) 5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer (Phila) 44:42–47PubMedGoogle Scholar
  74. 74.
    Sakata Y, Ohtsu A, Horikoshi N, et al (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1(1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720CrossRefPubMedGoogle Scholar
  75. 75.
    Hyodo I, Nishina T, Moriwaki T, et al (2003) A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 39:2328–2333CrossRefPubMedGoogle Scholar
  76. 76.
    Yoshida K, Hirabayashi N, Takiyama W, et al (2004) Phase I study of combination therapy wtih S-1 and docetaxel(TXT) for advanced or recurrent gastric cancer. Anticancer Res 24:1843–1851PubMedGoogle Scholar
  77. 77.
    Mitachi Y, Sakata Y, Ohtsu A, et al (2002) Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study. Gastric Cancer 5:160–167CrossRefPubMedGoogle Scholar
  78. 78.
    Shirao K, Shimada Y, Kondo H, et al (1997) Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921–927PubMedGoogle Scholar
  79. 79.
    Yoshida M, Boku N, Ohtsu A, et al (2001) Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer 4:144–149CrossRefPubMedGoogle Scholar
  80. 80.
    Skipper H, Schable FJ, Wilcox W (1964) Experimental evaluation of potential anticancer agent. XIII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 35:1–111PubMedGoogle Scholar
  81. 81.
    Foley J, Kessinger M, Lemon H (1980) Treatment of breast cancer with oral four-drug chemotherapy. J Surg Oncol 14:67–72PubMedGoogle Scholar
  82. 82.
    Tucker R, Ferguson A, Van Wyk C, et al (1978) Chemotherapy of small cell carcinoma of the lung with V.P.16 213. Cancer (Phila) 41:1710–1714PubMedGoogle Scholar
  83. 83.
    Hahn R, Moertel C, Schutt A, et al (1975) A double-blind comparison of intensive course 5-fluorouracil by oral vs intravenous route in the treatment of colorectal carcinoma. Cancer (Phila) 35:1031–1035PubMedGoogle Scholar
  84. 84.
    Chlebowski R, Paroly W, Pugh R, et al (1979) Treatment of advanced gastric carcinoma with 5-fluorouracil: randomized comparison of two routes of delivery. Cancer Treat Rep 63:1979–1981PubMedGoogle Scholar
  85. 85.
    Bedikian A, Staab R, Livingston R, et al (1978) Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. Cancer Treat Rep 62:1603–1605PubMedGoogle Scholar
  86. 86.
    Carmichael J, Popiela T, Radstone D, et al (2002) Randomized comparative study of Tegafur/Uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617–3627CrossRefPubMedGoogle Scholar
  87. 87.
    Douillard J-Y, Hoff P, Skillings J, et al (2002) Multicenter phase III study of Uracil/Tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605–3616CrossRefPubMedGoogle Scholar
  88. 88.
    Shirao K, Hoff P, Ohtsu A, et al (2004) Comparison of the efficacy, toxicity and pharmacokinetics of a Uracil/Tegafur(UFT) plus oral leucovorin(LV) regimen between Japanese and American patients with advanced colorectal cancer: Joint United State and Japan Study of UFT/LV. J Clin Oncol 22:3466–3474CrossRefPubMedGoogle Scholar
  89. 89.
    Feliu S, Gonzalez Baron M, Garcia-Giron C, et al (1996) Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. Cancer (Phila) 78:211–216CrossRefPubMedGoogle Scholar
  90. 90.
    Koizumi W, Kurihara M, Sasai T, et al (1993) A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer (Phila) 72:658–662PubMedGoogle Scholar
  91. 91.
    Koizumi W, Kurihara M, Hasegawa K, et al (1996) Combination therapy with cisplatin, 5′-deoxy-5-fluorouridine(5′-DFUR) and mitomycin (MMC) in patients with inoperable, advanced gastric cancer: a randomized trial comparing two dosage regimens. Oncol Rep 3:255–260Google Scholar
  92. 92.
    Koizumi W, Kurihara M, Nakano S, et al (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191–197CrossRefPubMedGoogle Scholar
  93. 93.
    Koizumi W, Tanabe S, Ohtsu A, et al (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207–2212CrossRefPubMedGoogle Scholar
  94. 94.
    Hoff P, Pazdur R, Benner S, et al (1998) UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anti-cancer Drugs 9:479–490PubMedGoogle Scholar
  95. 95.
    Inokuchi K, Akiyoshi T (1962) Catheterization into the caeliac artery for local chemotherapy (in Japanese). Shujutu 16:601–604Google Scholar
  96. 96.
    Watkins E Jr, Sullivan R (1964) Cancer chemotherapy by prolonged arterial infusion. Surg Gynecol Obstet 118:3–19PubMedGoogle Scholar
  97. 97.
    Miura K, Sugiura M, Ishida S, et al (1966) Intra-arterial chemotherapy with Watkins’ portable infusion pump (in Japanese). Ikakikaigaku Zasshi 36:504–508Google Scholar
  98. 98.
    Miura K, Wada T, Haida H, et al (1982) Subdermal implantable continuous infusion pump: Infusaid (in Japanese). Shujutu 36:1449–1458Google Scholar
  99. 99.
    Stephens FO, Adams BG, Crea P (1986) Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 162:370–374PubMedGoogle Scholar
  100. 100.
    Arai Y, Kido C, Endo T, et al (1989) Intra-arterial FAM chemotherapy for gastric cancer patients with liver metastasis (in Japanese). Gan to Kagakuryouhou 15:2433–2436Google Scholar
  101. 101.
    Aigner KR, Benthin F, Muler H (1991) Celiac axis infusion (CAI) chemotherapy for advanced gastric cancer. In: Sugarbaker PH (ed) Management of gastric cancer. Kluwer, Boston, pp 357–362Google Scholar
  102. 102.
    Nakajima T, Ota K, Ishihara S, et al (1997) Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4:203–208CrossRefPubMedGoogle Scholar
  103. 103.
    Takahashi Y, Mai M, Taguchi T, et al (2000) Prolonged stable disease effects survival in patients with solid gastric tumor: analysis of phase II studies of doxifluridine. Int J Oncol 17:285–289PubMedGoogle Scholar
  104. 104.
    Takahashi Y, Nishioka K (1995) Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87:1262–1263PubMedGoogle Scholar
  105. 105.
    Japanese Society of Clinical Oncology (1986) Response evaluation criteria of chemotherapy for solid cancer (in Japanese). J Jpn Soc Clin Oncol 21:929–942Google Scholar
  106. 106.
    Therasse P, Arbuch S, Eisenhauer E, et al (2000) New guideline to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  107. 107.
    JCOG (1999) NCI-CTC (in Japanese). Gan to Kagakuryouhou 26:1084–1144Google Scholar
  108. 108.
    Nakajima T, Nishi M (1988) Adjuvant chemotherapy, immunochemotherapy, and neoadjuvant therapy for gastric cancer in Japan. In: Douglass HO Jr (ed) Gastric cancer, vol 8. Churchill Livingstone, New York, pp 125–143Google Scholar
  109. 109.
    Nakajima T (1990) Adjuvant chemotherapy for gastric cancer in Japan: present status and suggestions for rational clinical trials. Jpn J Clin Oncol 20:30–42PubMedGoogle Scholar
  110. 110.
    Sano T, Sasako M, Katai H, et al (1999) Randomized controlled trials on adjuvant therapy for gastric cancer: Japanese experience. In: Nakajima T, Yamaguchi T (eds) Multimodality therapy for gastric cancer. Springer-Verlag, Tokyo, pp 7–16Google Scholar
  111. 111.
    Imanaga H, Nakazato H (1977) Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1:213–221CrossRefGoogle Scholar
  112. 112.
    Nakajima T, Fukami A, Ohashi I, et al (1978) Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol 16:209–216Google Scholar
  113. 113.
    Nakajima T, Fukami A, Takagi K, et al (1980) Adjuvant chemotherapy with mitomycin C, and with a multi-drug combination of mitomycin C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 10:187–194Google Scholar
  114. 114.
    Inokuchi K, Hattori T, Taguchi T, et al (1984) Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer (Phila) 53:2393–2397PubMedGoogle Scholar
  115. 115.
    Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122–1126CrossRefPubMedGoogle Scholar
  116. 116.
    Arima S, Ohsato K, Hisatsugu T, Shimura H (1994) Multicenter randomized study of adjuvant chemotherapy with mitomycin c and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 160:227–232PubMedGoogle Scholar
  117. 117.
    Furukawa H, Iwanaga T, Nakajima T, et al (1995) Randomized study with mitomycin C + 5-fluorouracil, cytosine arabinoside (MFC) + 5-fluorouracil, MFC + Tegafur and Uracil (UFT), and MF + UFT in advanced gastric cancer: interinstitutional differences in a multicenter study in Japan. J Surg Oncol 60:59–64PubMedGoogle Scholar
  118. 118.
    Sugimachi K, Maehara Y, Ogawa M, et al (1997) Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 40:233–238CrossRefPubMedGoogle Scholar
  119. 119.
    Nakajima T, Nashimoto A, Kitamura M, et al (1999) Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Lancet 354:273–277CrossRefPubMedGoogle Scholar
  120. 120.
    Nakajima T (2000) Evaluation of adjuvant UFT for gastric cancer. Oncology 14:82–86PubMedGoogle Scholar
  121. 121.
    Nashimoto A, Nakajima T, Furukawa H, et al (2003) Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 21:2282–2287CrossRefPubMedGoogle Scholar
  122. 122.
    Hermans J, Bonenkamp H (1994) In reply to the editor. J Clin Oncol 12:879–880Google Scholar
  123. 123.
    Nakajima T, Ohta K, Ishihara S, et al (1994) Evaluation of adjuvant chemotherapy in gastric cancer with meta-analysis. Cancer Chemother 21:1800–1805Google Scholar
  124. 124.
    Nakajima T, Ohta K, Ohyama S, et al (1999) Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital, Tokyo. In: Nakajima T, Yamaguchi T (eds) Multimodality therapy for gastric cancer. Springer-Verlag, Tokyo, pp 27–31Google Scholar
  125. 125.
    Earle C, Maroun J (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 35:1059–1064CrossRefPubMedGoogle Scholar
  126. 126.
    Mari E, Floriani I, Tinassi A, et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol 11:837–843CrossRefPubMedGoogle Scholar
  127. 127.
    Panzini I, Gianni L, Fattori P, et al (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88:21–27PubMedGoogle Scholar
  128. 128.
    Frei E, Miller ID, Clark JR, et al (1986) Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. Recent Results Cancer Res 103:1–5PubMedGoogle Scholar
  129. 129.
    Yonemura Y, Sawa T, Kinoshita K, et al (1993) Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17:256–261CrossRefPubMedGoogle Scholar
  130. 130.
    Suga S, Iwase H, Shimada M, et al (1996) Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Intern Med 35:930–936PubMedGoogle Scholar
  131. 131.
    Tei Y, Yamashita Y, Nakada B, et al (1995) Clinical effect of continuous iv 5-FU and low-dose daily CDDP regimen for advanced and recurrent gastric cancer (in Japanese). Gan to Kagakuryouhou 22:149–151Google Scholar
  132. 132.
    Kondou T, Murase M, Yokoyama T, et al (1996) Preoperative chemotherapy with continuous 5-FU and low-dose daily CDDP regimen for advanced and recurrent gastric cancer (in Japanese). Gan to Kagakuryouhou 23:1299–1303Google Scholar
  133. 133.
    Chung Y, Yamashita Y, Inoue T (1997) Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80:1–7CrossRefPubMedGoogle Scholar
  134. 134.
    Saikawa Y, Kanai T, Kawano Y, et al (2002) An experience of TS-1, low-dose CDDP regimen for gastric cancer patients with liver metastasis (in Japanese). Gan to Kagakuryouhou 29:1241–1245Google Scholar
  135. 135.
    Kelsen D, Ginsberg R, Pajak T, et al (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984CrossRefPubMedGoogle Scholar
  136. 136.
    Songun I, Keizer H, Hermans J, et al (1999) Chemotherapy for operable gastric cancer: results of the Dutch randomized FAMTX trial. Eur J Cancer 35:558–562CrossRefPubMedGoogle Scholar
  137. 137.
    Yamamoto T, Komechi T, Nishioka K, et al (1956) Cell agar plate (CAP) method as a chemosensitivity test (in Japanese). Gann 47:424–426Google Scholar
  138. 138.
    Nishioka K, Takehiko T, Yamamoto T, et al (1959) Chemo-sensitivity test for human anticancer virus and drugs (in Japanese). Nihon Rinshou 15:23–34Google Scholar
  139. 139.
    Ishibashi Y, Fujii G, Okada S (1957) Screening test for anti-cancer drugs with human cancer tissues (in Japanese). Rinshou no Nihon 3:141–149Google Scholar
  140. 140.
    Kondou T, Ichihashi H, Imamura T, et al (1964) Screening test of anti-cancer drugs (in Japanese). Gan no Rinshou 10:17–21Google Scholar
  141. 141.
    Ohsawa N (1975) Chemotherapy to the xenograft of human cancer tissue in nude mouse (in Japanese). Rinshou Seijinbyou 5:1039–1045Google Scholar
  142. 142.
    Tanigawa N (2004) Chemotherapy for gastrointestinal cancer (in Japanese). Nihon Medical Center, Tokyo, pp 7–57Google Scholar
  143. 143.
    Kubota T, Sasano N, Abe O (1995) Potential of the histoculture drug-responce assay to contribute to cancer patients survival. Clin Cancer Res 1:1537–1543PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2005

Authors and Affiliations

  • Toshifusa Nakajima
    • 1
  1. 1.Cancer Institute HospitalJapanese Foundation for Cancer Research (JFCR)TokyoJapan

Personalised recommendations